Center for the Evaluation of Biomarkers for the Early Detection of Breast Cancer
Abstract
Breast Cancer remains a leading cause of death for women in the US despite the popularity of mammography as a preventive tool. At diagnosis, many breast cancers are at an advanced stage of disease, even for women undergoing annual screening, resulting in costly and painful follow-up procedures. It has been shown by current clinical use of marker such as CA-125 and PSA that molecular markers can increase our ability to diagnose early stage tumors. By combining molecular diagnosis with current imaging analysis of breast tissue, we may further reduce the number of deaths as well as the number of women undergoing surgery unnecessarily. The translational goal of this Center of Excellence (CoE) is the development of a panel of serum markers with decision rules for its use to improve the performance of mammography and other breast cancer screening tools. This year we measured our most promising markers in serum and plasma specimens collected from CoE participants. The specimens are divided in two groups: a Panel Development Set (PDS) and a Panel Validation Set (PVS). Markers were measured in both groups but only results from the PDS have been analyzed. The results of this work are presented in the attached report and will be submitted next year in a manuscript for publication. Due to a limited number of candidate serum markers we have continued our efforts to identify new markers in tissue and to find or develop assays for marker evaluation. A manuscript reporting the results of these additional efforts was submitted for publication in September and another paper describing assay development techniques is in draft.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2009
- Accession Number
- ADA515793
Entities
People
- Nicole Urban
Organizations
- Fred Hutchinson Cancer Center